在宣布其针对罕见皮肤病的研究药物成功达成一项关键后期试验的主要目标后,Palvella Therapeutics的股价在盘前交易中大幅上涨了23%。这一积极结果极大地提振了投资者信心,预示着该疗法在寻求监管批准的道路上迈出了关键一步。该公司的前景因此次试验成功而显著改善。
在宣布其针对罕见皮肤病的研究药物成功达成一项关键后期试验的主要目标后,Palvella Therapeutics的股价在盘前交易中大幅上涨了23%。这一积极结果极大地提振了投资者信心,预示着该疗法在寻求监管批准的道路上迈出了关键一步。该公司的前景因此次试验成功而显著改善。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.